# "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

> **NCT00219011** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 280 (—)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** aliskiren

## Key facts

- **NCT ID:** NCT00219011
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 280 (—)
- **Last updated:** 2017-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219011, ""ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00219011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*